|Bid||0.0000 x 21500|
|Ask||0.0000 x 3000|
|Day's range||3.0000 - 3.1390|
|52-week range||3.0000 - 7.3400|
|Beta (5Y monthly)||1.99|
|PE ratio (TTM)||N/A|
|Earnings date||23 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||9.17|
The potential for four or more interest rate hikes by the Federal Reserve over the course of 2022 has been weighing heavily on growth stocks of late. Investors are clearly pivoting toward safe havens like value and dividend stocks ahead of this perceived eventuality. Shares of the cancer specialists Adaptimmune Therapeutics (NASDAQ: ADAP) and Clovis Oncology (NASDAQ: CLVS) are both trading at absurdly low valuations following their steep downturns over the past several weeks.
We discuss a few companies like BioMarin (BMRN), Adaptimmune (ADAP), CRISPR Therapeutics (CRSP), and Alnylam Pharmaceuticals (ALNY) with solid product portfolios, deep pipelines which make them attractive candidates for a potential takeover in 2022.
A mix of marketwide headwinds and company-specific events weighed on these three biotech stocks in November.